At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
Control-IQ technology 1.5device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Control-IQ Technology in Individuals With Type 2 Diabetes (2IQ)
In Brief
A clinical study evaluating Control-IQ technology 1.5 for Type 2 Diabetes Treated With Insulin. Completed, enrolled 30 participants across 3 sites.
Detailed Summary
A prospective, multicenter study of 6 weeks of home use of Control-IQ technology in individuals with type 2 diabetes age 18 and older.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Treated With Insulin
CountriesUnited States
CollaboratorsJaeb Center for Health Research
Timeline
N/ACompletedFinished
20222023202420252026
First PostedNov 2021
Enrollment StartNov 2021
Primary CompletionAug 2022
Study CompletionAug 2022
TodayJul 2026
First PostedNov 8, 2021
Enrollment StartNov 30, 2021
Primary CompletionAug 10, 2022
Study CompletionAug 18, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.6 years ago
Interventions
Control-IQ technology 1.5device
All subjects wearing the t-slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 sensor. Outcomes will be analyzed overall and subgroup analysis will be performed by Group, and by baseline A1c level.